River Street Advisors LLC Acquires Shares of 11,701 Zoetis Inc. $ZTS

River Street Advisors LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 11,701 shares of the company’s stock, valued at approximately $1,383,000.

A number of other institutional investors also recently modified their holdings of the business. Nordea Investment Management AB raised its stake in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares in the last quarter. Seilern Investment Management Ltd grew its position in Zoetis by 361.2% during the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after acquiring an additional 261,155 shares during the last quarter. Deutsche Bank AG grew its holdings in Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after acquiring an additional 891,921 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Zoetis by 134.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after purchasing an additional 935,432 shares during the last quarter. Finally, Pincus Capital Management LP acquired a new position in Zoetis in the fourth quarter valued at $2,109,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $76.05 on Friday. The stock’s fifty day moving average is $88.70 and its 200 day moving average is $110.94. The firm has a market capitalization of $31.88 billion, a PE ratio of 12.61, a PEG ratio of 1.21 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $161.77.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the previous year, the company posted $1.48 earnings per share. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 35.16%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ZTS. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Citigroup reduced their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Morgan Stanley reissued an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a report on Friday, May 15th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Finally, JPMorgan Chase & Co. reduced their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $133.08.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter, Bronstein Gewirtz & Grossman, and others, announced or promoted class-action claims against Zoetis, increasing legal overhang and sentiment pressure on the stock.
• Neutral Sentiment: Zoetis also said it will host a webcast and conference call on August 6, 2026 to discuss second-quarter results, which may provide a more fundamental update for investors. Article Title

Insider Activity at Zoetis

In other news, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 11,650 shares of company stock valued at $886,384 in the last ninety days. Company insiders own 0.22% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.